MA54865A - Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration - Google Patents

Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration

Info

Publication number
MA54865A
MA54865A MA054865A MA54865A MA54865A MA 54865 A MA54865 A MA 54865A MA 054865 A MA054865 A MA 054865A MA 54865 A MA54865 A MA 54865A MA 54865 A MA54865 A MA 54865A
Authority
MA
Morocco
Prior art keywords
furosemide
administration
methods
pharmaceutical formulations
concentrated liquid
Prior art date
Application number
MA054865A
Other languages
English (en)
Inventor
Alfredo Grossi
Franciscus Koppenhagen
Britt Kostraba
Olatokumbo O Luca Ogunleye
Shannon Terry
Original Assignee
Scpharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scpharmaceuticals Inc filed Critical Scpharmaceuticals Inc
Publication of MA54865A publication Critical patent/MA54865A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA054865A 2019-01-31 2020-01-30 Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration MA54865A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962799215P 2019-01-31 2019-01-31

Publications (1)

Publication Number Publication Date
MA54865A true MA54865A (fr) 2022-05-04

Family

ID=69740677

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054865A MA54865A (fr) 2019-01-31 2020-01-30 Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration

Country Status (14)

Country Link
US (5) US11998555B2 (fr)
EP (1) EP3917495A1 (fr)
JP (1) JP7465881B2 (fr)
KR (1) KR20210150360A (fr)
CN (1) CN113747881B (fr)
AU (1) AU2020214314A1 (fr)
BR (1) BR112021014637A2 (fr)
CA (1) CA3128033A1 (fr)
EA (1) EA202192129A1 (fr)
IL (1) IL285073A (fr)
MA (1) MA54865A (fr)
MX (1) MX2021009084A (fr)
SG (1) SG11202108280RA (fr)
WO (1) WO2020160210A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160210A1 (fr) 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
EP0416232B1 (fr) * 1989-08-21 1995-08-16 American Cyanamid Company Fomulation stable injectable à base d'acide folique et de sels de la leucovorine et méthode
ES2136090T3 (es) 1991-05-30 1999-11-16 Abbott Lab Reactivos que contienen un inhibidor de fijacion no especifico para analisis de fijacion con captura de iones.
US5633240A (en) 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
IT1283608B1 (it) 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
ES2313266T3 (es) 2005-12-28 2009-03-01 Sensile Pat Ag Microbomba.
EA018258B1 (ru) 2006-07-12 2013-06-28 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенный ациланилид и содержащие его композиции и способы лечения
EP2022518A1 (fr) 2007-08-07 2009-02-11 Sensile Pat AG Dispositif modulaire pour l'administration de doses divisées d'un médicament
US7923447B2 (en) 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
ES2546287T3 (es) 2008-05-16 2015-09-22 Corthera, Inc. Relaxina para uso en el tratamiento de la disnea asociada con la insuficiencia cardiaca aguda
EP2334302B1 (fr) 2008-09-09 2018-03-21 Cima Labs Inc Les formes posologiques pour les principes actifs qui sont faiblement ionisables
EP2473226A1 (fr) 2009-09-04 2012-07-11 Minipumps LLC Timbre transdermique adhésif avec pompe d'administration sous-cutanée de médicament
BR112014009634A2 (pt) 2011-10-19 2017-05-09 Mercator Medsystems Inc preparação e agente terapêutico
CN103371967A (zh) 2012-04-17 2013-10-30 上海禾丰制药有限公司 呋塞米注射液及其制剂工艺
MX369832B (es) * 2012-05-18 2019-11-22 Luoda Pharma Ltd Formulaciones líquidas que comprenden pimobendan y propilenglicol para el tratamiento de hipertensión y/o enfermedades cardiacas.
EP2981258B8 (fr) 2013-04-05 2020-11-11 scPharmaceuticals Inc. Formulations pharmaceutiques pour l'administration sous-cutanée de furosémide
US10320020B2 (en) 2014-10-29 2019-06-11 Nissan Motor Co., Ltd. Electrode catalyst for fuel cell, electrode catalyst layer for fuel cell, method for producing the same, and membrane electrode assembly and fuel cell using the catalyst layer
EP3893843A1 (fr) 2018-12-10 2021-10-20 SQ Innovation AG Compositions pharmaceutiques de furosémide et leurs utilisations
EP3906020A1 (fr) 2019-01-04 2021-11-10 SQ Innovation AG Compositions pharmaceutiques de torsémide et leurs utilisations
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
WO2020160210A1 (fr) 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration

Also Published As

Publication number Publication date
US11497755B2 (en) 2022-11-15
EP3917495A1 (fr) 2021-12-08
KR20210150360A (ko) 2021-12-10
EA202192129A1 (ru) 2021-10-19
CN113747881A (zh) 2021-12-03
US20230277558A1 (en) 2023-09-07
MX2021009084A (es) 2021-10-26
SG11202108280RA (en) 2021-08-30
US11559535B2 (en) 2023-01-24
US20220168323A1 (en) 2022-06-02
JP2022518900A (ja) 2022-03-17
US11571434B2 (en) 2023-02-07
CN113747881B (zh) 2024-05-14
AU2020214314A1 (en) 2021-08-19
WO2020160210A1 (fr) 2020-08-06
US20220378806A1 (en) 2022-12-01
US20220378805A1 (en) 2022-12-01
CA3128033A1 (fr) 2020-08-06
US20220096500A1 (en) 2022-03-31
BR112021014637A2 (pt) 2021-09-21
JP7465881B2 (ja) 2024-04-11
US11998555B2 (en) 2024-06-04
IL285073A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
PE20190738A1 (es) Formulacion novedosa para administracion por via oral
MA43172A (fr) Compositions pharmaceutiques et méthodes d'inhibition d'indolamine 2,3-dioxygénase et leurs indications
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
DK3727555T3 (da) Oral delivery of active drug substances
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
MY191980A (en) Formulations containing an extract of echinacea and linoleic acid derivatives
MA49023A (fr) Application d'un composé ou d'un extrait de médecine chinoise traditionnelle dans la préparation d'un agent d'administration d'acide nucléique et produits apparentés correspondants
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MA39443A1 (fr) Nouvelle formulation de méloxicam
MA48461A (fr) Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
IT201800001301A1 (it) Formulazioni in gel per la somministrazione orale di farmaci, in particolare nei pazienti disfagici
ES2850277R1 (es) Composiciones de administración farmacéutica y usos de las mismas
MA53333A (fr) Formulations pharmaceutiques d'anticorps masqués
MA54865A (fr) Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration
MA53669A (fr) Compositions et procédés d'administration d'acides nucléiques
IL283522A (en) Pharmaceutical preparations containing anti-191p4d12 antibody drug conjugates and methods of using them
EA201792237A1 (ru) Фармацевтические составы
MA55726A (fr) Associations thérapeutiques, compositions pharmaceutiques liquides, kits pour leur préparation et leurs méthodes d'utilisation
MA52587A (fr) Composés d'azabenzimidazole et produit pharmaceutique
MA44286A (fr) Formulation pharmaceutique de cinéol et d'amoxicilline
EA201400484A1 (ru) Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей
MA50458A (fr) Formulations topiques destinées au traitement d'affections dermatologiques comprenant la calvitie hippocratique
MA53852A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation